A robust biomarker discovery pipeline for high-performance mass spectrometry data

Journal of Bioinformatics and Computational Biology

Volumn 5, Issue 5, 2007, Pages 1023-1045

  Fisher, Wayne G ^a   Rosenblatt, Kevin P ^b   Fishman, David A ^c   Whitteley, Gordon R ^d   Mikulskis, Alvydas ^e   Kuzdzal, Scott A ^e   Lopez, Mary F ^f   Tan, Niclas Chiang ^a   German, Dwight C ^a   Garner, Harold R ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d SAIC FREDERICK INC   (United States)

^e PERKINELMER INC   (United States)

^f Thermo Fisher Scientific   (United States)

Author keywords

Biomarkers; Mass spectra; Ovarian cancer

Indexed keywords

CA 125 ANTIGEN;

ACCURACY; ARTICLE; BIOINFORMATICS; CANCER STAGING; COMPUTER PROGRAM; CONTROLLED STUDY; DATA EXTRACTION; DIAGNOSTIC VALUE; DISEASE MARKER; FEMALE; HUMAN; LEARNING ALGORITHM; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; NORMAL DISTRIBUTION; OVARY CANCER; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY;

ALGORITHMS; BIOLOGICAL MARKERS; CA-125 ANTIGEN; COMPUTATIONAL BIOLOGY; DATA INTERPRETATION, STATISTICAL; FEMALE; HUMANS; MASS SPECTROMETRY; OVARIAN NEOPLASMS; PROTEOME; SOFTWARE; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL;

EID: 35348901937     PISSN: 02197200     EISSN: None     Source Type: Journal    
DOI: 10.1142/S021972000700303X     Document Type: Article

References (35)

1. Rifai N, Gillette MA, Carr SA, Protein biomarker discovery and validation: The long and uncertain path to clinical utility, Nat Biotechnol 24(8):971-983, 2006.
2. Rosenblatt KP, Bryant-Greenwood P, Killian JK, Mehta A, Geho D, Espina V, Petricoin EF, Liotta LA, Serum proteomics in cancer diagnosis and management, Annu Rev Med 55:97-112, 2004.
3. Villanueva J, Philip J, Chaparro CA, Li Y, Toledo-Crow R, DeNoyer L, Fleisher M, Robbins RJ, Tempst P, Correcting common errors in identifying cancer-specific serum peptide signatures, J Proteome Res 4(4):1060-1072, 2005.
4. Ressom HW, Varghese RS, Abdel-Hamid M, Eissa SA, Saha, D, Goldman L, Petricoin EF, Conrads TP, Veenstra, TD, Loffredo CA, Goldman R, Analysis of mass spectral serum profiles for biomarker selection, Bioinformatics 21(21):4039-4045, 2005.
5. Sidransky D, Irizarry R, Califano JA, Li X, Ren H, Benoit N, Mao L, Serum protein MALDI profiling to distinguish upper aerodigestive tract cancer patients from control subjects, J Natl Cancer Inst 95 22):1711-1717, 2003.
6. Zhang Z, Bast RCJ, Yu Y, Li J, Sokoll LJ, Rai AJ, Rosenzweig JM, Cameron B, Wang YY, Meng X, Berchuck A, Van Haaften-Day C, Hacker NF, de Bruijn HWA, van der Zee AGJ, Jacobs IJ, Fung ET, Chan DW, Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer, Cancer Res 64(16):5882-5890, 2004.
7. Lopez MF, Mikulskis A, Kuzdzal S, Bennett DA, Kelly J, Golenko E, DiCesare J, Denoyer E, Patton WF, Ediger R, Sapp L, Ziegert T, Lynch C, Kramer S, Whiteley GR, Wall MR, Mannion DP, Della Cioppa G, Rakitan JS, Wolfe GM, High-resolution serum proteomic profiling of Alzheimer disease samples reveals disease-specific, carrier-protein-bound mass signatures, Clin Chem 51(10):1946-1954, 2005.
8. Conrads TP, Pusaro VA, Ross S, Johann D, Rajapakse V, Hitt BA, Steinberg SM, Kohn EC, Fishman DA, Whitely G, Barrett JC, Liotta LA, Petricoin III EF, Veenstra TD, High-resolution serum proteomic features for ovarian cancer detection, Endocr Relat Cancer 11(2):163-178, 2004.
9. Purohit P, Rocke D, An H, Miyamoto, S, Lebrilla C, Multivariate analysis of glycomic mass spectrometry data, Nineth Int Conf Res Comput Mol Biol, RECOMB, 2005.
10. Ornstein DK, Rayford W, Fusaro VA, Conrads TP, Ross SJ, Hitt BA, Wiggins WW, Veenstra TD, Liotta LA, Petricoin EF, Serum proteomic profiling can discriminate prostate cancer from benign prostates in men with total prostate specific antigen levels between 2.5 and 15.0 ng/ml, J Urol 172(4 Part 1):1302-1305, 2004.
11. Zhu W, Wang X, Ma Y, Rao M, Glimm J, Kovach JS, Detection of cancer-specific markers amid massive mass spectral data, Proc Natl Acad Sci USA 100(25):14666-14671, 2003.
12. Kozak KR, Amneus MW, Pusey SM, Su F, Luong MN, Luong SA, Reddy ST, Farias-Eisner R, Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: Potential use in diagnosis and prognosis, Proc Natl Acad Sci USA 100(21):12343-12348, 2003.
13. Ball G, Mian S, Holding F, Allibone RO, Lowe J, Ali S, Li G, McCardle S., Ellis IO, Creaser C, Rees RC, An integrated approach utilizing artificial neural networks and SELDI mass spectrometry for the classification of human tumours and rapid identification of potential biomarkers, Bioinformatics 18(3):395-404, 2002.
14. Petricoin EF, Zoon KC, Kohn EC, Barrett JC, Liotta LA, Clinical proteomics: Translating benchside promise into bedside reality, Nat Rev Drug Discov 1(9):683-695, 2002.
15. Qu Y, Adam B, Yasui Y, Ward MD, Cazares LH, Schellhammer PF, Feng Z, Semmes OJ, Wright GLJ, Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from non-cancer patients, Clin Chem 48(10):1835-1843, 2002.
16. Lilien RH, Farid H, Donald BR, Probabilistic disease classification of expression-dependent proteomic data from mass spectrometry of human serum, J Comput Biol 10(6):925-946, 2003.
17. Rai AJ, Zhang Z, Rosenzweig J, Shih I, Pham T, Fung ET, Sokoll LJ, Chan DW, Proteomic approaches to tumor marker discovery, Arch Pathol Lab Med 126(12):1518-1526, 2002.
18. Li J, Zhang Z, Rosenzweig J, Wang YY, Chan DW, Proteomics and boinformatics approaches for identification of serum biomarkers to detect breast cancer, Clin Chem 48(8):1296-1304, 2002.
19. Poon TCW, Yip T, Chan ATC, Yip C, Yip V, Mok TSK, Lee CCY, Leung TWT, Ho SKW, Johnson PJ, Comprehensive proteomic profiling identifies serum proteomic signatures for detection of hepatocellular carcinoma and its subtypes, Clin Chem 49(5):752-760, 2003.
20. Tusher VG, Tibshirani R, Chu G, Significance analysis of microarrays applied to the ionizing radiation response, Proc Natl Acad Sci USA 98(9):5116-5121, 2001.
21. Villanueva J, Philip J, Entenberg D, Chaparro CA, Tanwar MK, Holland EC, Tempst P, Serum peptide profiling by magnetic particle-assisted, automated sample processing and MALDI-TOF mass spectrometry, Anal Chem 76(6):1560-1570, 2004.
22. Weil MR, Rosenblatt KP, Garner HR, Analysis of serum proteome patterns in cancer patients, personal communication.
23. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, Mills GB, Simone C, Fishman DA, Kohn EC, Liotta LA, Use of proteomic patterns in serum to identify ovarian cancer, Lancet 359 9306):572-577, 2002.
24. Conrads TP, Zhou M, Petricoin III EF, Liotta L, Veenstra TD, Cancer diagnosis using proteomic patterns, Expert Rev Mol Diagn 3 4):411-420, 2003.
25. Cohen J, Statistical Power Analysis for the Behavioral Sciences, Academic Press, Orlando, FL, 1977.
26. Loboda AV, Ackloo S, Chernushevich IV, A high-performance matrix-assisted laser desorption/ionization orthogonal time-of-flight mass spectrometer with collisional cooling, Rapid Commun Mass Spectrom 17(22):2508-2516, 2003.
27. Savitzky A, Golay MJE, Smoothing and differentiation of data by simplified least squares procedures, Anal Chem 36:1627-1639, 1964.
28. Davidson B, Risberg B, Goldberg I, Nesland JM, Berner A, Trope CG, Kristensen GB, Bryne M, Reich R, ETS-1 mRNA expression in effusions of serous ovarian carcinoma patients is a marker of poor outcome, Am J Surg Pathol 25(12):1493-1500, 2001.
29. Takai N, Miyazaki T, Nishida M, Nasu K, Miyakawa, I, C-ETS1 is a promising marker in epithelial ovarian cancer, Int J Mol Med 9 3):287-292, 2002.
30. Newcombe RG, Interval estimation for the difference between independent proportions: Comparison of eleven methods, Stat Med 17 8):873-890, 1998.
31. Moss EL, Hollingworth J, Reynolds TM, The role of CA125 in clinical practice, J Clin Pathol 58(3):308-312, 2005.
32. Diamandis EP, Analysis of serum proteomic patterns for early cancer diagnosis: Drawing attention to potential problems, J Natl Cancer Inst 96(5):353-356, 2004.
33. Ransohoff DF, Bias as a threat to the validity of cancer molecular-marker research, Nat Rev Cancer 5:142-149, 2005.
34. Thompson IM, Ankerst DP, Chi C, Lucia MS, Goodman PJ, Crowley-JJ, Parnes HL, Coltman CAJ, Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/mL or lower, JAMA 294(1):66-70, 2005.
35. German DC, Gurnani P, Nandi A, Garner HR, Diaz-Arrastia R, O'Suilleabhain P, Rosenblatt KP, Serum biomarkers for Alzheimer's disease: Proteomic discovery, Biomed Pharmacother 61 383-389, 2007.